Circio Holding ASA (OSL:CRNA) Land And Improvements : kr0.00 Mil (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Circio Holding ASA Land And Improvements?

Circio Holding ASA's land and improvements for the quarter that ended in Dec. 2023 was kr0.00 Mil.

Circio Holding ASA Land And Improvements Historical Data

The historical data trend for Circio Holding ASA's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Circio Holding ASA Land And Improvements Chart

Circio Holding ASA Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Land And Improvements

Get a 7-Day Free Trial

Circio Holding ASA Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Dec23
Land And Improvements	Get a 7-Day Free Trial															-	-	-	-	-

Circio Holding ASA Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Circio Holding ASA (OSL:CRNA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Circio Holding ASA (OSL:CRNA) » Definitions » Land And Improvements

Comparable Companies

Traded in Other Exchanges

TA50:Germany

Address

Vollsveien 19, Lysaker, Oslo, NOR, 1366

Website

https://www.circio.com

Circio Holding ASA is a clinical-stage company. It is focused on developing and commercializing immuno-oncology therapies to target treatment-resistant solid tumors. Its product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to infect cancer cells and activate the immune system to fight cancer. It includes the development and implementation with the purpose of developing targeted immunotherapy treatments for cancer patients.

Circio Holding ASA (OSL:CRNA) Headlines

No Headlines